GPCR biased ligands as novel heart failure therapeutics

被引：29
作者：
Violin, Jonathan D. [1 ]
Soergel, David G. [1 ]
Boerrigter, Guido [2 ]
Burnett, John C., Jr. [2 ]
Lark, Michael W. [1 ]
机构：
[1] Treuena Inc, King Of Prussia, PA 19406 USA
[2] Mayo Clin & Mayo Fdn, Cardiorenal Res Lab, Rochester, MN 55905 USA
来源：
TRENDS IN CARDIOVASCULAR MEDICINE | 2013年 / 23卷 / 07期
关键词：
ANGIOTENSIN-II RECEPTOR; WORSENING RENAL-FUNCTION; BETA-ARRESTIN; CLINICAL-TRIALS; PATHWAYS; 1A; ACTIVATION; HYPERTENSION; MANAGEMENT; THERAPY;
D O I：
10.1016/j.tcm.2013.01.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
G protein-coupled receptors have been successfully targeted by numerous therapeutics including drugs that have transformed the management of cardiovascular disease. However, many GPCRs, when activated or blocked by drugs, elicit both beneficial and adverse pharmacology. Recent work has demonstrated that in some cases, the salutary and deleterious signals linked to a specific GPCR can be selectively targeted by "biased ligands" that entrain subsets of a receptor's normal pharmacology. This review briefly summarizes the advances and current state of the biased ligand field, focusing on an example: biased ligands targeting the angiotensin II type 1 receptor. These compounds exhibit unique pharmacology, distinct from classic agonists or antagonists, and one such molecule is now in clinical development for the treatment of acute heart failure. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码：242 / 249
页数：8
相关论文
共 64 条
[11]   Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure [J].
Chen, HH ;
Redfield, MM ;
Nordstrom, LJ ;
Cataliotti, A ;
Burnett, JC .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2003, 284 (05) :F1115-F1119
[12]   LOSARTAN IN HEART-FAILURE - HEMODYNAMIC-EFFECTS AND TOLERABILITY [J].
CROZIER, I ;
IKRAM, H ;
AWAN, N ;
CLELAND, J ;
STEPHEN, N ;
DICKSTEIN, K ;
FREY, M ;
YOUNG, J ;
KLINGER, G ;
MAKRIS, L ;
RUCINSKA, E .
CIRCULATION, 1995, 91 (03) :691-697
[13]  
DELEAN A, 1980, J BIOL CHEM, V255, P7108
[14]   β-arrestin-mediated signaling regulates protein synthesis [J].
Dewire, Scott M. ;
Kim, Jihee ;
Whalen, Erin J. ;
Ahn, Seungkirl ;
Chen, Minyong ;
Lefkowitz, Robert J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (16) :10611-10620
[15]   β-arrestins and cell signaling [J].
DeWire, Scott M. ;
Ahn, Seungkirl ;
Lefkowitz, Robert J. ;
Shenoy, Sudha K. .
ANNUAL REVIEW OF PHYSIOLOGY, 2007, 69 :483-510
[16]   Biased Ligands for Better Cardiovascular Drugs Dissecting G-Protein-Coupled Receptor Pharmacology [J].
DeWire, Scott M. ;
Violin, Jonathan D. .
CIRCULATION RESEARCH, 2011, 109 (02) :205-216
[17]   The Positive Inotropic Effect of Relaxin-2 in Human Atrial Myocardium is Preserved in End-Stage Heart Failure: Role of Gi-Phosphoinositide-3 Kinase Signaling [J].
Dschietzig, Thomas ;
Alexiou, Konstantin ;
Kinkel, Hans-Tilman ;
Baumann, Gert ;
Matschke, Klaus ;
Stangl, Karl .
JOURNAL OF CARDIAC FAILURE, 2011, 17 (02) :158-166
[18]   Intravenous Recombinant Human Relaxin in Compensated Heart Failure: A Safety, Tolerability, and Pharmacodynamic Trial [J].
Dschietzig, Thomas ;
Teichman, Sam ;
Unemori, Elaine ;
Wood, Susy ;
Boehmer, Julia ;
Richter, Christoph ;
Baumann, Gert ;
Stangl, Karl .
JOURNAL OF CARDIAC FAILURE, 2009, 15 (03) :182-190
[19]   Cardiovascular effects of relaxin: from basic science to clinical therapy [J].
Du, Xiao-Jun ;
Bathgate, Ross A. D. ;
Samuel, Chrishan S. ;
Dart, Anthony M. ;
Summers, Roger J. .
NATURE REVIEWS CARDIOLOGY, 2010, 7 (01) :48-58
[20]   A transgenic mouse model of heart failure using inducible Gαq [J].
Fan, GF ;
Jiang, YP ;
Lu, ZJ ;
Martin, DW ;
Kelly, DJ ;
Zuckerman, JM ;
Ballou, LM ;
Cohen, IS ;
Lin, RZ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (48) :40337-40346
1234567